$SPRO News

Spero Therapeutics, Inc. Q2 2026 Earnings Call Summary

Spero Therapeutics Q2 Earnings Call Highlights

Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

Innovent licenses IBI355 rights to Spero for up to $1.1bn

Spero Therapeutics: 'Buy' On Utebzi Royalty Deal For Funding And SP001 In-Licensing

Spero Therapeutics Lands $105 Million Royalty Financing to Advance SP001 Development (SPRO)

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

Spero Therapeutics Announces $105M In Non-Recourse Non-Dilutive Royalty Financing With KKR's Healthcare Royalty

Spero Therapeutics Enters License Agreement With Innovent Biologics For Exclusive Rights To Develop, Research, Manufacture, And Commercialize SP001 Globally Ex-China

GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs

Spero Shares Jump After FDA Clears First Oral Carbapenem Antibiotic for U.S. Market (SPRO)

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

Spero Therapeutics: Approval Upside, Commercial Friction (Initiating Hold)

Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update

Spero Therapeutics Q1 EPS $(0.13) Beats $(0.18) Estimate, Sales $258.000K Down From $5.874M YoY